{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T14:57:38Z","timestamp":1770562658470,"version":"3.49.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001169","name":"Cancer Council Tasmania","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001169","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.clon.2022.02.004","type":"journal-article","created":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T11:57:39Z","timestamp":1645703859000},"page":"e183-e194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Single-Fraction Stereotactic Ablative Body Radiotherapy to the Lung \u2013 The Knockout Punch"],"prefix":"10.1016","volume":"34","author":[{"given":"M.C.","family":"Tjong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.V.","family":"Louie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.K.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Videtic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Stephans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Plumridge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6067-7177","authenticated-orcid":false,"given":"S.","family":"Harden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9902-4592","authenticated-orcid":false,"given":"B.J.","family":"Slotman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Alongi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Guckenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Siva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2022.02.004_bib1","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.prro.2017.04.014","article-title":"Stereotactic body radiation therapy for early-stage non-small cell lung cancer: executive summary of an ASTRO evidence-based guideline","volume":"7","author":"Videtic","year":"2017","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.clon.2022.02.004_bib2","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.18.00622","article-title":"Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non-small-cell lung cancer: NRG Oncology\/RTOG 0813 trial","volume":"37","author":"Bezjak","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2022.02.004_bib3","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.adro.2020.06.011","article-title":"Single-fraction stereotactic body radiation therapy: a paradigm during the coronavirus disease 2019 (COVID-19) pandemic and beyond?","volume":"5","author":"Ng","year":"2020","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.clon.2022.02.004_bib4","doi-asserted-by":"crossref","first-page":"E119","DOI":"10.1016\/j.clon.2017.02.004","article-title":"Stereotactic ablative body radiotherapy for the treatment of spinal oligometastases","volume":"29","author":"Chang","year":"2017","journal-title":"Clin Oncol"},{"key":"10.1016\/j.clon.2022.02.004_bib5","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1001\/jamaoncol.2019.5351","article-title":"Stereotactic ablative radiotherapy for the management of spinal metastases: a review","volume":"6","author":"Glicksman","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clon.2022.02.004_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.01219","article-title":"Stereotactic body radiotherapy for oligometastatic disease in non-small cell lung cancer","volume":"9","author":"Wujanto","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.clon.2022.02.004_bib7","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S1470-2045(15)70168-3","article-title":"Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials","volume":"16","author":"Chang","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2022.02.004_bib8","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1748-717X-1-30","article-title":"Stereotactic, single-dose irradiation of stage I non-small cell lung cancer and lung metastases","volume":"1","author":"Fritz","year":"2006","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.clon.2022.02.004_bib9","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMct0806951","article-title":"Stereotactic radiosurgery for the treatment of brain metastases","volume":"362","author":"Suh","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clon.2022.02.004_bib10","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.radonc.2020.04.001","article-title":"Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: an ESTRO-ASTRO consensus statement","volume":"146","author":"Guckenberger","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2022.02.004_bib11","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.ijrobp.2018.11.051","article-title":"Long term follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): a randomized phase II study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer","volume":"103","author":"Videtic","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2022.02.004_bib12","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ijrobp.2017.01.040","article-title":"A\u00a0phase 2 randomized study of 2 stereotactic body radiation therapy regimens for medically inoperable patients with node-negative, peripheral non-small cell lung cancer","volume":"98","author":"Singh","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2022.02.004_bib13","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.ijrobp.2019.08.019","article-title":"One versus three fractions of stereotactic body radiation therapy for peripheral stage I to II non-small cell lung cancer: a randomized, multi-institution, phase 2 trial","volume":"105","author":"Singh","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2022.02.004_bib14","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1001\/jamaoncol.2018.1258","article-title":"Long-term results of stereotactic body radiation therapy in medically inoperable stage I non-small cell lung cancer","volume":"4","author":"Timmerman","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clon.2022.02.004_bib15","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ijrobp.2021.05.116","article-title":"Ten-year experience in implementing single-fraction lung SBRT for medically inoperable early stage lung cancer","volume":"111","author":"Videtic","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2022.02.004_bib16","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1001\/jamaoncol.2021.2939","article-title":"Single-fraction vs multifraction stereotactic ablative body radiotherapy for pulmonary oligometastases (SAFRON II): the Trans Tasman Radiation Oncology Group 13.01 phase 2 randomized clinical trial","volume":"7","author":"Siva","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clon.2022.02.004_bib17","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cllc.2013.06.006","article-title":"Clinical outcomes of single dose stereotactic radiotherapy for lung metastases","volume":"14","author":"Osti","year":"2013","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.clon.2022.02.004_bib18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.7785\/tcrt.2012.500355","article-title":"Outcomes of single fraction stereotactic ablative radiotherapy for lung metastases","volume":"13","author":"Filippi","year":"2014","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.clon.2022.02.004_bib19","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00066-007-1724-z","article-title":"Stereotactic single-dose radiotherapy of lung metastases","volume":"183","author":"Hof","year":"2007","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.clon.2022.02.004_bib20","series-title":"Stereotactic radiotherapy for pulmonary oligometastases from colorectal cancer: a systematic review and meta-analysis","author":"Jingu","year":"2018"},{"key":"10.1016\/j.clon.2022.02.004_bib21","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.lungcan.2018.06.018","article-title":"30 Gy single dose stereotactic body radiation therapy (SBRT): report on outcome in a large series of patients with lung oligometastatic disease","volume":"122","author":"Osti","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.clon.2022.02.004_bib22","doi-asserted-by":"crossref","first-page":"315","DOI":"10.21873\/anticanres.11323","article-title":"Stereotactic body radiotherapy in patients with lung oligometastases from colorectal cancer","volume":"37","author":"Pasqualetti","year":"2017","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clon.2022.02.004_bib23","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ijrobp.2014.10.021","article-title":"Stereotactic body radiation therapy for oligometastases to the lung: a phase 2 study","volume":"91","author":"Nuyttens","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2022.02.004_bib24","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1097\/JTO.0b013e3181de7143","article-title":"Stereotactic radiotherapy for pulmonary oligometastases: a systematic review","volume":"5","author":"Siva","year":"2010","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.clon.2022.02.004_bib25","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1186\/s12885-020-06892-4","article-title":"Radiosurgery and fractionated stereotactic body radiotherapy for patients with lung oligometastases","volume":"20","author":"Kalinauskaite","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clon.2022.02.004_bib26","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ijrobp.2017.02.093","article-title":"Stereotactic ablative radiation therapy for pulmonary metastases: histology, dose, and indication matter","volume":"98","author":"Helou","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2022.02.004_bib27","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1080\/0284186X.2018.1445285","article-title":"Factors affecting local control of pulmonary oligometastases treated with stereotactic body radiotherapy","volume":"57","author":"Sharma","year":"2018","journal-title":"Acta Oncol"},{"key":"10.1016\/j.clon.2022.02.004_bib28","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1200\/JCO.2008.19.6386","article-title":"Multi-institutional phase I\/II trial of stereotactic body radiation therapy for lung metastases","volume":"27","author":"Rusthoven","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2022.02.004_bib29","doi-asserted-by":"crossref","first-page":"S135","DOI":"10.21037\/tlcr.2019.08.08","article-title":"Safety of stereotactic ablative body radiation for ultracentral stage I non-small cell lung cancer","volume":"8","author":"Wu","year":"2019","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.clon.2022.02.004_bib30","first-page":"325","article-title":"Mortality following single-fraction stereotactic body radiation therapy for central pulmonary oligometastasis","volume":"4","author":"Ma","year":"2017","journal-title":"J\u00a0Radiosurg SBRT"},{"key":"10.1016\/j.clon.2022.02.004_bib31","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1097\/01243894-200610000-00008","article-title":"Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors","volume":"1","author":"Le","year":"2006","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.clon.2022.02.004_bib32","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1200\/JCO.2006.07.5937","article-title":"Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer","volume":"24","author":"Timmerman","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2022.02.004_bib33","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.jtho.2021.03.019","article-title":"The HILUS-Trial\u2014a prospective nordic multicenter phase 2 study of ultracentral lung tumors treated with stereotactic body radiotherapy","volume":"16","author":"Lindberg","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.clon.2022.02.004_bib34","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1017\/S1460396917000061","article-title":"Comparison of single- and five-fraction schedules of stereotactic body radiation therapy for central lung tumours: a single institution experience","volume":"16","author":"Ma","year":"2017","journal-title":"J\u00a0Radiother Pract"},{"key":"10.1016\/j.clon.2022.02.004_bib35","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ijrobp.2015.07.2260","article-title":"NRG Oncology RTOG 0915 (NCCTG N0927): a randomized phase II study comparing 2 stereotactic body radiation therapy (SBRT) schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer","volume":"93","author":"Videtic","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2022.02.004_bib36","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1016\/j.prro.2021.03.005","article-title":"Organ at risk dose constraints in SABR: a systematic review of active clinical trials","volume":"11","author":"Gerhard","year":"2021","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.clon.2022.02.004_bib37","doi-asserted-by":"crossref","first-page":"e187","DOI":"10.1016\/j.prro.2018.11.011","article-title":"Effect of tumor location and dosimetric predictors for chest wall toxicity in single-fraction stereotactic body radiation therapy for stage I non-small cell lung cancer","volume":"9","author":"Manyam","year":"2019","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.clon.2022.02.004_bib38","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.radonc.2009.04.018","article-title":"Brachial plexopathy from stereotactic body radiotherapy in early-stage NSCLC: dose-limiting toxicity in apical tumor sites","volume":"93","author":"Forquer","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2022.02.004_bib40","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.ijrobp.2007.10.059","article-title":"Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy","volume":"70","author":"Park","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2022.02.004_bib41","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.semradonc.2015.11.001","article-title":"Validity of current stereotactic body radiation therapy dose constraints for aorta and major vessels","volume":"26","author":"Xue","year":"2016","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.clon.2022.02.004_bib42","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.ijrobp.2014.06.066","article-title":"Single- versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: outcomes and toxicity","volume":"90","author":"Pollom","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2022.02.004_bib43","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.radonc.2013.09.005","article-title":"Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancer","volume":"109","author":"Guckenberger","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2022.02.004_bib44","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijrobp.2019.02.047","article-title":"Biological principles of stereotactic body radiation therapy (SBRT) and stereotactic radiation surgery (SRS): indirect cell death","volume":"110","author":"Song","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2022.02.004_bib45","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.ijrobp.2018.03.045","article-title":"(18)F-EF5 PET-based imageable hypoxia predicts local recurrence in tumors treated with highly conformal radiation therapy","volume":"102","author":"Qian","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2022.02.004_bib46","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.ijrobp.2018.12.041","article-title":"Single fraction SBRT for early stage lung cancer\u2014less is more?","volume":"103","author":"Siva","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2022.02.004_bib47","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.clon.2020.05.001","article-title":"Reduced fractionation in lung cancer patients treated with curative intent radiotherapy during the COVID-19 pandemic","volume":"32","author":"Faivre-finn","year":"2020","journal-title":"Clin Oncol"},{"key":"10.1016\/j.clon.2022.02.004_bib48","series-title":"J\u00a0Thorac Oncol Conf 18th World Conf Lung Cancer Int Assoc Study Lung Cancer, IASLC 2017 Japan","first-page":"S1853","article-title":"Long term follow-up on NRG oncology RTOG 0915 (NCCTG N0927): a randomized phase II study of 2 SBRT schedules for lung cancer","volume":"12","author":"Videtic","year":"2017"},{"key":"10.1016\/j.clon.2022.02.004_bib49","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1120\/jacmp.v17i3.6077","article-title":"Assessment of Monte Carlo algorithm for compliance with RTOG 0915 dosimetric criteria in peripheral lung cancer patients treated with stereotactic body radiotherapy","volume":"17","author":"Pokhrel","year":"2016","journal-title":"J\u00a0Appl Clin Med Phys"},{"key":"10.1016\/j.clon.2022.02.004_bib50","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ijrobp.2011.12.005","article-title":"Dosimetric verification using Monte Carlo calculations for tissue heterogeneity-corrected conformal treatment plans following RTOG 0813 dosimetric criteria for lung cancer stereotactic body radiotherapy","volume":"84","author":"Li","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2022.02.004_bib51","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.phro.2020.05.002","article-title":"Delivery of magnetic resonance-guided single-fraction stereotactic lung radiotherapy","volume":"14","author":"Finazzi","year":"2020","journal-title":"Phys Imaging Radiat Oncol"},{"key":"10.1016\/j.clon.2022.02.004_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2012.00153","article-title":"Radiation as an immunological adjuvant: current evidence on dose and fractionation","volume":"2","author":"Demaria","year":"2012","journal-title":"Front Oncol"},{"key":"10.1016\/j.clon.2022.02.004_bib53","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ijrobp.2012.12.025","article-title":"Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas","volume":"86","author":"Zeng","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2022.02.004_bib54","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.clon.2019.04.006","article-title":"The abscopal effect of stereotactic radiotherapy and immunotherapy: fool\u2019s Gold or El Dorado?","volume":"31","author":"Xing","year":"2019","journal-title":"Clin Oncol"},{"key":"10.1016\/j.clon.2022.02.004_bib55","doi-asserted-by":"crossref","first-page":"5055","DOI":"10.1158\/1078-0432.CCR-16-2946","article-title":"A\u00a0pilot study of stereotactic body radiation therapy combined with cytoreductive nephrectomy for metastatic renal cell carcinoma","volume":"23","author":"Singh","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clon.2022.02.004_bib56","doi-asserted-by":"crossref","first-page":"23721","DOI":"10.1073\/pnas.2001933117","article-title":"Radiation induces dynamic changes to the T cell repertoire in renal cell carcinoma patients","volume":"117","author":"Chow","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clon.2022.02.004_bib57","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1395996","article-title":"PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation","volume":"7","author":"Morisada","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.clon.2022.02.004_bib58","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.ijrobp.2011.09.049","article-title":"Maximizing tumor immunity with fractionated radiation","volume":"83","author":"Schaue","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2022.02.004_bib59","doi-asserted-by":"crossref","first-page":"S248","DOI":"10.1016\/j.jtho.2019.08.493","article-title":"MA01.01 Safety of pembrolizumab combined with stereotactic ablative body radiotherapy (SABR) for pulmonary oligometastases","volume":"14","author":"Siva","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.clon.2022.02.004_bib60","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","article-title":"Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial","volume":"5","author":"Theelen","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clon.2022.02.004_bib61","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-016-2227-z","article-title":"A\u00a0randomised phase II trial of stereotactic ablative fractionated radiotherapy versus radiosurgery for oligometastatic neoplasia to the lung (TROG 13.01 SAFRON II)","volume":"16","author":"Siva","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clon.2022.02.004_bib62","doi-asserted-by":"crossref","first-page":"e767","DOI":"10.1016\/j.ijrobp.2010.10.074","article-title":"Cost-effectiveness analysis of stereotactic body radiotherapy and radiofrequency ablation for medically inoperable, early-stage non-small cell lung cancer","volume":"81","author":"Sher","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2022.02.004_bib63","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1001\/jamaoncol.2019.1449","article-title":"Pembrolizumab after completion of locally ablative therapy for oligometastatic non-small cell lung cancer: a phase 2 trial","volume":"5","author":"Bauml","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clon.2022.02.004_bib64","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/OP.21.00200","article-title":"Payment methodology for the radiation oncology alternative payment model: implications for practices and suggestions for improvement","volume":"17","author":"Boyce-Fappiano","year":"2021","journal-title":"JCO Oncol Pract"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655522000887?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655522000887?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:51:25Z","timestamp":1760543485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655522000887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":63,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0936655522000887"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2022.02.004","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Single-Fraction Stereotactic Ablative Body Radiotherapy to the Lung \u2013 The Knockout Punch","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2022.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}